
The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services. The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

SB 253 Original

DIGEST
2026 Regular Session

McMath

Proposed law provides that no professional or occupational licensing board shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides shipped from a FDA-registered 503B facility or a 503A compounding pharmacy that buys its active pharmaceutical ingredients from an FDA-registered manufacturer.

Proposed law requires the prescribing provider to ensure any peptides prescribed pursuant to proposed law are not on the FDA's prohibited compounding list.

Effective August 1, 2026.

(Adds R.S. 37:23.5)